Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
It is widely believed that the nigrostriatal toxicity of MPTP is due to its oxidation by brain monoamine oxidase first to MPDP+, and eventually to MPP+. Following uptake by the synaptic dopamine reuptake system, it is concentrated in the matrix of striatal mitochondria by an energy-dependent carrier, energized by the electrical gradient of the membrane. At the very high intramitochondrial concentrations thus reached, MPP+ combines with NADH dehydrogenase at a point distal to its iron-sulfur clusters but prior to the Q10 combining site. This leads to cessation of oxidative phosphorylation, ATP depletion, and cell death. Other pyridine derivatives act similarly on NADH dehydrogenase but they are not acutely toxic unless concentrated by the MPP+ carrier.
Singer
T P
TP
Department of Pharmacy, University of California, San Francisco 94143.
Ramsay
R R
RR
McKeown
K
K
Trevor
A
A
Castagnoli
N E
NE
D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001921:Brain / Q000201:enzymology; D008928:Mitochondria / Q000187:drug effects*; D008995:Monoamine Oxidase / Q000502:physiology; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009247:NADH, NADPH Oxidoreductases / Q000037:antagonists & inhibitors; D010300:Parkinson Disease / Q000473:pathology; D011725:Pyridines / Q000633:toxicity; D011726:Pyridinium Compounds / Q000493:pharmacokinetics / Q000633:toxicity*
D009097:Multienzyme Complexes; D011725:Pyridines; D011726:Pyridinium Compounds; D008995:Monoamine Oxidase; C023107:NADH oxidase; D009247:NADH, NADPH Oxidoreductases; D015655:1-Methyl-4-phenylpyridinium